Movement Alert｜KEYMED BIO-B Falls 5.63% in Regular Trading, UBS Downgrade Weighs on Shares

Market Focus10-22

On October 22, KEYMED BIO-B fell 5.63% in Regular Trading, trading at HK$81.3, with turnover of HK$110 million.

The clearest catalyst in public information is a newly reported broker action: UBS downgraded the stock to Neutral and set a target price of RMB27, which aligns with the latest negative price move.

This pullback comes even though the company had recently disclosed stronger operating momentum. Its core product Kangyueda generated about RMB660 million of revenue in the first three quarters, up about 227% year over year, driven by expanding market demand and rapid hospital access growth. A new indication for adolescent moderate-to-severe atopic dermatitis was also approved, while the product had already been included in the national reimbursement drug list and national essential medicines list. Even so, the most recent public development tied to the current weakness is the rating downgrade rather than those earlier positive updates.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment